-
公开(公告)号：US20150307475A1
公开(公告)日：2015-10-29
申请号：US14653649
申请日：2013-12-17
Applicant: NOVARTIS AG
Inventor： Vikkie Furminger , Owen Rhys Hughes , Darren Mark Legrand , Emily Stanley , Christopher Thomson
IPC: C07D401/12 , A61K31/454
CPC classification number: C07D401/12 , A61K31/4192 , A61K31/445 , A61K31/454 , A61K31/46 , A61K31/496 , A61K31/5375 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D211/26 , C07D211/32 , C07D211/34 , C07D211/58 , C07D211/60 , C07D249/04 , C07D263/38 , C07D265/30 , C07D401/06 , C07D403/06 , C07D403/12 , C07D413/12 , C07D417/12 , C07D451/04
Abstract: The present invention relates to novel compounds of formula (I) (I) that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-dependent or ATX-mediated disease or condition.
Abstract translation: 本发明涉及新型的式（I）（I）化合物，其为自分泌抑素，其制备方法，药物组合物和含有它们的药物及其用于治疗ATX依赖性或ATX介导的疾病或病症 。
-
公开(公告)号：USRE46757E1
公开(公告)日：2018-03-20
申请号：US14755691
申请日：2015-06-30
Applicant: Novartis AG
Inventor： Urs Baettig , Kamlesh Jagdis Bala , Emma Budd , Lee Edwards , Catherine Howsham , Glyn Alan Hughes , Darren Mark Legrand , Katrin Spiegel
IPC: A61K31/5355 , C07D213/26 , A61K31/4965 , A61K31/4453 , C07D241/16 , C07D213/04 , C07D213/61 , C07D413/12 , C07D211/06 , A61K31/497 , C07D213/22 , A61K31/445 , A61K31/444 , A61K31/443 , A61K31/454 , A61K31/44 , A61K31/4439 , A61K31/4418 , A61K31/4545 , A61K31/4412 , A61K31/5377 , A61K45/06 , C07D213/81 , C07D241/28 , C07D241/26 , C07D213/38 , C07D401/12 , C07D401/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D413/04
CPC classification number: A61K31/44 , A61K31/4412 , A61K31/4418 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4965 , A61K31/497 , A61K31/5377 , A61K45/06 , C07D213/38 , C07D213/81 , C07D241/26 , C07D241/28 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/12 , C07D413/04 , C07D413/12
Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
-
公开(公告)号：US09763957B2
公开(公告)日：2017-09-19
申请号：US14906161
申请日：2014-07-16
Applicant: Novartis AG
Inventor： David Beattie , Urs Baettig , Darren Mark Legrand , Andrew Stuart Lister , Jeffrey McKenna , David William Pearce , David Andrew Sandham , Oliver Ross Steward , Christopher Thomson
IPC: A61K31/445 , A61K31/551 , C07D403/12 , C07D401/14 , C07D413/14 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/5377 , A61K31/5513 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/14 , C07D407/12 , C07D413/10 , C07D413/12 , C07D417/10 , C07D417/14 , C07D257/04 , A61K45/06 , A61K31/45 , A61K31/496 , A61K31/504 , A61K31/439 , A61K31/454 , A61K31/4545 , A61K31/506 , C07D405/12 , C07D471/08
CPC classification number: A61K31/551 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/439 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/504 , A61K31/506 , A61K31/5377 , A61K31/5513 , A61K45/06 , C07D257/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D417/14 , C07D471/08 , A61K2300/00
Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
-
公开(公告)号：US09365552B2
公开(公告)日：2016-06-14
申请号：US14521843
申请日：2014-10-23
Applicant: Novartis AG
Inventor： Urs Baettig , Kamlesh Bala , Emma Budd , Lee Edwards , Catherine Howsham , Glyn Alan Hughes , Darren Mark Legrand , Katrin Spiegel
IPC: A61K31/44 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4965 , A61K31/497 , A61K31/5377 , A61K31/4418 , A61K45/06 , C07D405/04 , C07D213/81 , C07D241/28 , C07D401/04 , C07D405/12 , C07D413/04 , C07D413/12 , C07D213/38 , C07D401/12 , C07D403/12 , A61K31/4412
CPC classification number: A61K31/44 , A61K31/4412 , A61K31/4418 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4965 , A61K31/497 , A61K31/5377 , A61K45/06 , C07D213/38 , C07D213/81 , C07D241/26 , C07D241/28 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/12 , C07D413/04 , C07D413/12
Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
-
-
-
Search Results
4
records
(took 0.02 seconds)
